News and Events

News

February 4, 2025

Strike Pharma presents updates at CICON24

Strike Pharma presents updates at CICON24

February 4, 2025

Strike Pharma granted patent to protect core technology

Strike Pharma has been granted a patent in Japan (JP 2021-529122), protecting the company’s core ADAC technology

February 4, 2025

Strike Pharma receives funding from BIO-X Accelerate program

The project is financed by the European Regional Development Fund (ERDF) through The Swedish Agency for Economic and Regional Growth via STUNS program BIO-X Accelerate

February 4, 2025

Strike Pharma and FyoniBio conclude successful cell line development of Strike’s bi-specific antibody and clinical lead candidate

FyoniBio to present data at PEGS Boston 2023

February 4, 2025

Funds awarded to study ADAC™ technology in depth

Research to be supported by Cancerfonden, one of Sweden’s largest financiers of cancer research

February 4, 2025

Strike Pharma continues expansion of management team

Joacim Elmén appointed as Director, CMC

February 4, 2025

Strike Pharma and FyoniBio sign Master Service Agreement

Agreement covers Cell Line Development for a novel bi-specific therapeutic mAb

February 4, 2025

Strike Pharma’s Chief Scientific Officer receives BiotechBuilders Award 2022

Dr. Sara Mangsbo acknowledged for entrepreneurship and her contribution to Swedish life science industry

February 4, 2025

Strike Pharma strengthens Board of Directors

Niclas Stiernholm elected as Chairman of the Board

February 4, 2025

Strike Pharma begins expansion of management team

Appoints Lindvi Gudmunsdotter as Director, Non-Clinical Development

February 4, 2025

Strike Pharma completes 45 MSEK financing round

Efforts now focus on bringing first candidate to clinical trials and further development of ADAC technology platform

February 4, 2025

Strike raises SEK 10M (>1M $)

Swedish immuno-oncology newcomer STRIKE Pharma raises SEK 10 million for development of individualized solid tumour therapy.

February 4, 2025

Mårten Winge new CEO

STRIKE Pharma appoints industry veteran Mårten Winge as new CEO

Events

February 4, 2025

Strike Pharma presents further developments at CICON23

Scientists from Strike Pharma presented two scientific posters demonstrating progress in the preclinical development of STRIKE2001-KRAS and in the use of the ADAC technology platform for drug cargo delivery.

February 4, 2025

Strike Pharma presents latest developments at AACR 2023

Chief Scientific Officer, Associate Professor Sara Mangsbo, presented some of the latest data demonstrating progress in the development of the ADAC technology platform for precision cancer immunotherapy.

February 4, 2025

Strike Pharma, Uppsala University and KTH Royal Institute of Technology present at CIMT 2022

CD40 agonistic, bispecific antibody candidates developed using ADAC technology ensure T-cell activation

February 4, 2025

Strike Pharma and Uppsala University present at AACR 2022

New data demonstrates proof of concept for ADAC technology platform